Simpler Grants.gov #RFA-CA-28-004

NCI Funding to Continue Clinical-Trial Biospecimen Bank Operations

The National Institutes of Health, through the National Cancer Institute, seeks eligible institutions to continue operating clinical-trial biospecimen banks for cancer research. - Government buyer: National Institutes of Health (NIH), National Cancer Institute (NCI). - Requested work: Continue the National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank), including collection, processing, storage, and distribution of clinically annotated human biospecimens from NCI-funded clinical trials. - NCTN banks support biomarker development and validation, correlative studies, and broader scientific discovery. - The EET Biobank supports research on investigational agents, including biomarker assays, pharmacokinetic and pharmacodynamic analyses, drug response and resistance, and patient stratification. - Funding and scale: The opportunity anticipates six awards and $19 million in program funding. - Eligibility and notable requirements: Limited to existing recipients of an NCTN biobank funded under RFA-CA-20-002 or an EET Biobank funded under RFA-CA-20-003. Foreign organizations and foreign components are ineligible. - OEMs and vendors: None identified. No specific products, part numbers, or quantities are listed.

Description

This Notice of Funding Opportunity invites eligible organizations to apply for continued support of two biospecimen banking resources: the NCI National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank). The resources collect, process, store, and distribute high-quality, clinically annotated human biospecimens from NCI-funded clinical trials to support translational cancer research. NCTN Biobanks support biomarker research and scientific discovery, while the EET Biobank supports research involving investigational agents, including biomarker assays, pharmacokinetic and pharmacodynamic analyses, and study of drug response and resistance. Eligibility is limited to recipients of an existing NCTN biobank funded under RFA-CA-20-002 or an existing EET Biobank under RFA-CA-20-003; foreign organizations and foreign components are not eligible.

View original listing